Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 13.98 | 0.06 | -0.02 |
| FCF Yield | -12.66% | -0.01% | -10.65% | -20.95% |
| EV / EBITDA | -7.05 | -3.58 | -15.18 | -4.20 |
| Quality | ||||
| ROIC | -68.87% | -0.04% | -37.49% | -61.15% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.76 | 0.64 | 0.84 | 1.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -76,485.25% | 99.92% | 13.88% | -40.30% |
| Safety | ||||
| Net Debt / EBITDA | -1.04 | -0.24 | -0.90 | -0.05 |
| Interest Coverage | -20.70 | -0.01 | -14.61 | -26.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -3,993.62 |
| Cash Conversion Cycle | -193.63 | -86.36 | -83.35 | -92.57 |